<DOC>
	<DOCNO>NCT00550563</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . PURPOSE : This clinical trial study change DNA affect vitamin D metabolism patient colorectal cancer receive vitamin D supplement .</brief_summary>
	<brief_title>DNA Changes That Affect Vitamin D Metabolism Patients With Colorectal Cancer Receiving Vitamin D Supplements</brief_title>
	<detailed_description>OBJECTIVES : - To identify CYP24 single nucleotide polymorphism ( SNPs ) use peripheral blood mononuclear cell genomic DNA patient colorectal cancer receive cholecalciferol supplementation . - To evaluate effect CYP24 SNPs baseline serum vitamin D_3 metabolite ( 25-D_3 , 24,25-D_3 , 1,25-D_3 ) , parathyroid hormone level ( PTH ) . - To evaluate effect CYP24 SNPs serum vitamin D_3 metabolites PTH level cholecalciferol treatment . - To examine CYP24 splicing , protein expression , enzyme activity baseline cholecalciferol treatment . - To determine relationship , , serum cholecalciferol pharmacokinetic parameter CYP24 SNPs , splice variant , enzyme activity . OUTLINE : Patients receive oral cholecalciferol 2000 IU daily 1 year . Patients without response vitamin D supplementation ( serum 25-D_3 level &lt; 32 ng/mL ) 6 month cholecalciferol dose increased 4000 IU daily . Blood collect baseline day 14 , 30 , 60 , 90 , 180 , 270 , 360 . Peripheral blood mononuclear cell CYP24 genotyping , protein expression , enzyme activity , splice variant analyzed polymerase chain reaction ( PCR ) , western blot , high performance liquid chromatography , reverse transcriptase PCR , respectively . Serum analyze vitamin D_3 metabolite level ( radioimmunoassay ) , calcium ( monitor hypercalcemia ) , parathyroid hormone assay ( measure vitamin D effect ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Prior current document diagnosis colorectal cancer All stag 25OHD3 level &lt; 50 ng/mL PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 6 month Serum creatinine &lt; 2.0 mg/dL Serum bilirubin &lt; 2.0 mg/dL No prior current hypercalcemia ( define albumin correct serum calcium &lt; 10.2 mg/dL ) No know contraindication vitamin D supplementation No genitourinary stone within past 5 year No severe comorbid condition uncompensated heart failure active infection PRIOR CONCURRENT THERAPY : No supplemental vitamin D beyond provide study At least 2 month since prior vitamin D supplementation exceed 800 International Units ( IU ) Nondietary vitamin D supplement exceed 800 IU/day within past 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>